Table 1.
Select demographics and baseline characteristics of BEACON patients
| Intent‐to‐treat population | ||
|---|---|---|
| Placebo (n = 1,097) | Bardoxolone methyl (n = 1,088) | |
| Age, year, mean ± SD | 68.2 ± 9.4 | 68.9 ± 9.7 |
| Female [n, %] | 472 [43] | 462 [42] |
| Race [n, %] | ||
| White | 848 [77] | 846 [78] |
| Black | 176 [16] | 185 [17] |
| Other | 73 [7] | 57 [5] |
| Serum creatinine, mg/dL, mean ± SD | 2.7 ± 0.6 | 2.7 ± 0.6 |
| eGFR, mL/min/1.73 m2, mean ± SD | 22.5 ± 4.6 | 22.4 ± 4.3 |
| UACR, mg/g, geometric mean | 221 | 210 |
| HbA1c, %, mean ± SD | 7.10 ± 1.17 | 7.15 ± 1.27 |
| ALT, U/L, mean ± SD | 18.4 ± 6.9 | 18.7 ± 7.1 |
| AST, U/L, mean ± SD | 19.5 ± 5.3 | 19.9 ± 5.7 |
| Total bilirubin, mg/dL, mean ± SD | 0.32 ± 0.14 | 0.33 ± 0.14 |
Partially reproduced from: Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. De Zeeuw et al. N Engl. J. Med. 369:2495, Copyright © 2013. 10
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BEACON, Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes; eGFR, estimated glomerular filtration rate; UACR, urinary albumin creatinine ratio; U/L, units per liter.